ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201833
CHEMBL1201833
Compound Name GOLIMUMAB
ChEMBL Synonyms CNTO-148 | GOLIMUMAB | CNTO 148 | Simponi
Max Phase 4 (Approved)
Trade Names Simponi

Sources

  • British National Formulary
  • Clinical Candidates
  • Manually Added Drugs
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL1201833 compound icon
Drug Type:Antibody Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
TNF-alpha inhibitor TNF-alpha DailyMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
ARTHRITIS, RHEUMATOIDD001172EFO:0000685RHEUMATOID ARTHRITIS4ClinicalTrials
DailyMed
DailyMed
SARCOIDOSISD012507Orphanet:797SARCOIDOSIS2ClinicalTrials
ASTHMAD001249EFO:0000270ASTHMA2ClinicalTrials
COLITIS, ULCERATIVED003093EFO:0000729ULCERATIVE COLITIS4ClinicalTrials
DailyMed
ARTHRITIS, PSORIATICD015535EFO:0003778PSORIATIC ARTHRITIS4ClinicalTrials
DailyMed
DIABETES MELLITUS, TYPE 1D003922EFO:0001359TYPE I DIABETES MELLITUS2ClinicalTrials
SPONDYLARTHROPATHIESD025242EFO:0000706SPONDYLOARTHROPATHY3ClinicalTrials
SPONDYLITIS, ANKYLOSINGD013167EFO:0003898ANKYLOSING SPONDYLITIS4ClinicalTrials
DailyMed

Clinical Data

ClinicalTrials.gov GOLIMUMAB
The Cochrane Collaboration GOLIMUMAB

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 - IMMUNOSUPPRESSANTS
L04A - IMMUNOSUPPRESSANTS
L04AB - Tumor necrosis factor alpha (TNF-α) inhibitors
L04AB06 - golimumab

ChemSpider ChemSpider Identifier not yet assigned
DailyMed golimumab
Wikipedia Golimumab
spacer
spacer